Carbylan BioSurgery Announces Positive Clinical Trial Results for Hydros-TA in Patients with Pain from Knee Osteoarthritis

July 26, 2011

Carbylan BioSurgery announced positive results in its double-blinded, multi-center clinical trial which evaluated the safety and effectiveness of Hydros-TA Joint Therapy and Hydros as compared to Synvisc-One in patients with osteoarthritis of the knee.
SYS-CON

UK Study Says Single Shot of Pfizer/BioNTech Vaccine Significantly Lessened Asymptomatic Infections

Carbylan BioSurgery Announces Positive Clinical Trial Results for Hydros-TA in Patients with Pain from Knee Osteoarthritis

Upcoming Events

FDA Drug GMP Facility Inspections During the Pandemic

Pharmaceutical Naming Regulation: Understanding the Latest Developments

Pharmaceutical Postmarket Surveillance: Latest Developments in the Era of COVID-19

Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

Data Integrity for GMP/Postmarket Professionals: Core Requirements, Expectations and Challenges

Medical Device Cybersecurity: Understand the Latest Developments

Featured Products

Biological Risk Evaluation and Management for Medical Devices

GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

UK Study Says Single Shot of Pfizer/BioNTech Vaccine Significantly Lessened Asymptomatic Infections

Eurofins Receives FDA Emergency Authorization for Over-the-Counter COVID-19 Test

Vetex Medical’s Thrombectomy Catheter Cleared by FDA

Merck Purchases Rights to Debiopharm’s Xevinapant for More Than $1 Billion

The Revised ICH E8: A Guide to New Clinical Trial Requirements